Retinoblastoma comprises about 3% of all the malignant tumours of childhood. The tumour may occur in only one or in both eyes and may be either unifocal or multifocal in origin. It occurs in both sporadic and inherited forms: the latter, which accounts for about 40% of all the cases, includes all bilateral tumours and a small proportion of unilateral tumours. The observed pattern of inheritance is consistent with that of an autosomal dominant gene.
Kundson' suggested that retinoblastoma is caused by mutational events in homologous genes on each of a pair of cumulative rate by age 5 of 55 per million. Our figures are lower than the actual incidence in Britain because we are including only patients registered with retinoblastoma at local cancer registries. It is known that some patients, particularly those who died without treatment, have never been registered, and it is possible that incidence rates quoted here should be increased by as much as 10%.
Of the 699 cases included in the analysis only four were diagnosed more than eight years after birth; the diagnosis of one bilateral case at age 10 years is remarkable. As can be seen from Table 1 the age distributions for unilateral and bilateral cases are quite different. Nearly all bilateral cases are diagnosed in thie first three years of life; more than a quarter of unilateral cases are diagnosed after this. Most cases in both groups are diagnosed during the 
TYPES OF TUMOUR AND FAMILY HISTORIES
The 431 children in the present study are classified in Table 3 by sex, laterality of the tumours, and whether or not there is a known family history of retinoblastoma. There is histological confirmation of the retinoblastoma for 399 of these patients. The incidence is similar for the two sexes: 221 boys and 210 girls were affected. In 149 (34.6%) children the tumours were bilateral and in 282 (65-4%) children unilateral. Of the unilateral tumours 156 were sited in the right eye and 126 in the left. For one additional child registered during the study period retinoblastoma cells were found only in the suprasellar region of the brain, the eyes and the optic nerves being free of tumour; she has not been included in the analysis. This child had a strong family history of retinoblastoma; her sister and mother were both affected. Fifty-three children had at least one other relative who had been diagnosed with retinoblastoma. This is 12% of all the children in the study and is in line with other published figures. It is notable that even for the bilateral cases only a minority, 26%, are known to have a family history. Forty children had a parent previously diagnosed with retinoblastoma, and 16 of this group of 40 children had at least one sibling with retinoblastoma. Three other children had one sibling with retinoblastoma, and 10 children in the study had only a more distant relative affected with the disease. Of the remaining 378 children with no known family history of retinoblastoma those with bilateral tumours are classified as having the genetic form of the disease. One patient with bilateral tumours included in this study, who was first treated at the age of 10 years, has recently had a child diagnosed with retinoblastoma at the age of 2 months. The study included a pair of monozygotic twins both of whom had retinoblastoma. One child was affected unilaterally, and the tumour regressed spontaneously without treatment. His brother, who had bilateral tumours, received radiotherapy to one eye, and the tumour in the other eye also regressed without treatment. One child with unilateral retinoblastoma had an unaffected monozygotic co-twin.
AGES AT DIAGNOSIS
The ages of the children when retinoblastoma was diagnosed ranged from 18 days to 10 years. Table 4 shows the distribution of ages for children with unilateral and bilateral tumours, subdivided according to whether or not there was a family history. These age distributions reflect the incidence rates shown in Table 1 . Bilateral cases were diagnosed at an earlier age than unilateral ones; in addition, within each group cases with a family history tended to be diagnosed earlier than those without. The unilateral tumours with no family history had their peak incidence between 24 and 29 months; more than half these children were diagnosed before the age of 30 months. The genetic tumours (bilateral or with a known family history) had their peak incidence in the first six months of life; more than half this group of children were treated before the age of 1 year.
For 130 of the 149 children with bilateral retinoblastoma the interval between diagnosis of the tumours in the two eyes was three months or less. For only six children was this interval longer than a year, and the longest interval was under three years. However, the fact that, when a tumour is discovered in one eye, the other eye is always examined care-fully, will probably mean that the second tumour is diagnosed earlier than would otherwise be the case and hence reduce the interval between the two diagnoses.
STAGING
The tumours were staged on the basis of medical records and histology by a modification of the system described by Reece and Ellsworth. Their five-part staging requires more detailed clinical information than that available for most of the cases in this study. The stages used and the numbers of unilateral and For 29 children the drugs were given because of a local recurrence of the retinoblastoma or distant metastases; all but one of these children died. The child who survived had been treated for six months with cyclophosphamide and vincristine as well as radiotherapy for a recurrence in the orbit and antrum which occurred 18 months after enucleation.8
SURVIVAL RATES AND CAUSES OF DEATHS
Three years after their initial treatment for retinoblastoma 374 of the 431 children were known to be still alive. Two children were lost to follow-up in this period. Of the 55 deaths three were from causes unrelated to retinoblastoma and three from ectopic intracranial retinoblastoma in the pineal gland or suprasellar region. The actuarially calculated threeyear survival rate, with deaths from unrelated causes being regarded as losses to follow-up, was 88%. The survival curves for the 282 unilateral and 149 bilateral cases are shown in Fig. 1 . The three-year survival rate for the bilateral group (90-5%) was slightly better than that for the unilateral one (86.5%). This is similar to the finding in our previous (1962-8) series. Thus in retinoblastoma most of the deaths occur within three years and are directly attributable to the original disease; very few deaths occur after this. Virtually all of these are in the bilateral group and the great majority are due either to ectopic intracranial retinoblastoma or to second primary neoplasms. The long-term survival rate for the bilateral group becomes worse than that for the unilateral group. The effects of various factors on the three-year survival rate are summarised in Table 9 .
Tumour stage and age at diagnosis. The staging system used in this paper is described above. As would be expected, there were large and highly significant differences in survival for the different groups (Table 9 ). It can also be seen from Table 9 that older children, that is, those aged 2 years or more at the time of diagnosis, tended to have a worse prognosis. This is largely accounted for by the fact that these children tended to be diagnosed at a more advanced stage. Sex. The overall survival rate for males was better than for females in both the unilateral and bilateral groups. The difference is significant (p<0-05) for the unilateral group and for the two groups combined. This finding is largely attributable to differences in the age and stage distribution for males and females. Treatment hospitals. Just over a quarter of the unilateral cases and nearly two-thirds of the bilateral cases were given their initial treatment at two London hospitals working jointly as the major United Kingdom referral centre for retinoblastoma. The three-year survival rates for patients treated initially at this centre were 91% and 94% respectively for unilateral and bilateral cases. These were slightly better than those for other specialist eye hospitals (89% and 91%), which in turn were better than those for the remaining hospitals. After allowance is made for the effects of stage and age at diagnosis there is a significant trend (p=0014) in survival rate for the unilateral cases; patients treated at the major centre have the best outcome followed by those treated at specialist eye hospitals. A similar analysis for the bilateral cases shows that the difference is not statistically significant. It is possible that this is because the major centre is actually treating the more difficult cases but the staging system used here is not sufficiently sensitive to reveal the effects of such case selection.
SECOND PRIMARY NEOPLASMS
In the present series five children developed second primary neoplasms: four of these were osteosarcomas, three of the leg and one of the orbit, and the fifth child developed acute lymphatic leukaemia. Three of these children have died.
In all, among the 699 children treated for retinoblastoma between 1962 and 1980, and included in our Thirteen of these children have since developed second primary neoplasms of a distinct histology from retinoblastoma, and 11 of the children have died from the second neoplasm. Of the total of 13 cases, three osteosarcomas, one brain tumour, and two fibrosarcomas developed within the radiation field. One child treated with high doses of radiation developed leukaemia. These seven second primary neoplasms could have been attributed at least partly to radiotherapy given to the retinoblastoma. However, the other six children all developed osteosarcomas of the leg, outside any field of radiation; indeed one child received no radiotherapy for the earlier retinoblastoma. Nine of 13 children who developed second primary neoplasms had been given cyclophosphamide as part of their treatment. This is a higher proportion than would have been expected from the proportion of patients known to be treatd with cyclophosphamide. However, patients treated with this drug are not representative of the total group of patients, and it is hard to say whether or not it was a factor in the causation of some of the second tumours. A full discussion is given in Draper et al.9
Discussion
The incidence of retinoblastoma found in the present paper is similar to that from earlier reports. We have found no evidence of a change in incidence in recent years. The age distributions are presented here in more detail than in earlier publications and show the well known difference in age distributions for unilateral and bilateral cases; the latter have a much earlier onset. More than half the genetic tumours were treated under the age of 1 year. On the assumption that two mutational events are necessary for the development of retinoblastoma,"' this earlier age of onset can be explained by the fact that in genetic cases the first mutation for the retinoblastoma gene is inherited and present in every cell in the body.
Ectopic intracranial retinoblastoma was recognised as a clinical entity only in 1977." During the period covered by the present study eight cases of retinoblastoma followed by ectopic intracranial retinoblastoma were identified, a proportion of 1 There has been a continuing trend towards centralisation of treatment for bilateral cases. In the period 1962-8 50% of the children with bilateral tumours received their initial treatment at the major UK referral centre; by 1969-80 this proportion had increased to 63%. The proportion of children with unilateral tumours treated at this major centre (27%) was almost identical in the two periods.
There has been very little change in the already high three-year survival rate for retinoblastoma in Britain between the periods 1962-8 and 1969-80, the high survival rate being due to the policy of referral to specialist centres. The great majority of deaths from retinoblastoma occur within three years of diagnosis. Beyond that period, for survivors from genetic retinoblastoma the risk of developing second primary neoplasms assumes an increasing importance in childhood and adult life. The cumulative incidence rate of all second primary neoplasms among survivors from genetic retinoblastoma has been reported as 8*4% after 18 years;9 for osteosarcoma alone the corresponding figure is 6%. It is now thought'3 that some osteosarcomas may be associated with homozygosity or hemizygosity of the mutant allele at the retinoblastoma locus-13q14 and that the same mutation may predispose towards osteosarcoma. 
